NCT06400589
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
A Phase 3, Multicenter, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% and 1.0% Compared to Vehicle in Participants With Dry Eye Disease (VELOS-4)
HanAll BioPharma Co., Ltd.·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Dry Eye
- Drug/Device/Intervention
- tanfanercept
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- HanAll BioPharma Co., Ltd.
- Location
- Delray Beach, United States of America
Timeline & enrollment
- Phase
- Phase 3
- Start date
- May 01, 2024
- End date
- Aug 01, 2025
- Enrollment
- 750 participants
Primary outcome
Schirmer Test
Summary
The objectives of this study are to compare the efficacy and safety of tanfanercept
 ophthalmic solution 0.25% and 1.0% to vehicle for the treatment of DED.
ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06400589
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06400589 through Pure Global AI's free database. This Phase 3 trial is sponsored by HanAll BioPharma Co., Ltd. and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 750 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.